• Home
  • Agenda
  • Speakers
  • Partners
    • Commercial Partners
    • Media Partners
    • Become a Commercial Partner
    • Host a webinar
  • Summit Details
    • Venue & Accommodation
    • FAQS
    • Sign up for conference updates
    • Contact Us
  • Attendance
    • Why attend
    • Gallery
    • Audience Breakdown
    • Poster Competition
    • Ticket details
  • DDF Summits
    • DDF Global
    • DDF Asia
  • LOG IN
  • Book now
Captisol
www.captisol.com

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Amgen’s Kyprolis®, Baxter International’s Nexterone®, Spectrum’s EVOMELA® and Melinta Therapeutics’ Baxdela™. There are many Captisol-enabled products currently in various stages of development.

Back

Information


Mark Allen Group
St Jude’s Church
Dulwich Road
London
SE24 0PB
United Kingdom

Main reception at Publication company: +44 (0)20 7738 5454


Additional Enquiries:


Alexandra Krcho, Account Director +44 (0)20 3874 9205
Adrian Forde, Delegate Sales Director + 44 (0)20 3874 9209

[Privacy Policy] – Please read our privacy policy to understand how we process, use, and safeguard your data.

Further information


Privacy policy

Cookie policy

Terms and conditions

Booking terms and conditions